Pharmacy First PGDs

The Pharmacy First service also currently includes 10 PGDs for the treatment of impetigo, uncomplicated UTI, skin infections, shingles and hayfever. See details below for the current PGDs and related documents.These can be found on our PGD page

Impetigo

• PGD for Fusidic Acid 2% Cream (review date August 2027)
• Impetigo patient assessment form (review date August 2027)
• Impetigo assessment form WORD
• GP Notification Form

Uncomplicated UTI

Please note the following changes to the Lothian versions of these PGDS compared to the national specimen:

For Trimethoprim and Nitrofurantoin:

A statement has been added about referring to East Region Formulary for information on first or second choice medicines

A note in the patient advice section that said to avoid double voiding has been amended (removed avoid)

 For Trimethoprim :

A statement has been added to the interactions section “Take particular care to consider serious interactions with medicines that may be supplied through other routes, for example methotrexate or clozapine.”

• PGD for Trimethoprim (review date August 2027)
• PGD for Nitrofurantoin (review date August 2027) 
• UTI patient assessment form PDF
• UTI patient assessment form WORD
• GP Notification Form

Skin Infection

• PGD for Flucloxacillin 
• Skin infection patient assessment form
• GP notification form

Shingles 

• PGD for Aciclovir 
• Shingles patient assessment form
• GP notification form

Hayfever 

• PGD for Beclometasone 
• PGD for Olopatadine 
• PGD for Mometasone 
• PGD for Fexofenadine 
• Hayfever patient assessment & GP notification form

Inflammatory Skin Conditions

PGD for Hydrocortisone 1% cream/ointment (Review date January 2028)

Inflammatory skin conditions patient assessment & GP notification form

Oral Thrush

Please note the following changes to the Lothian version of this PGD compared to the national specimen

1. Under Authorisation: addition of the statement: However, if the PGD is past the EXPIRY DATE it cannot legally be used to supply medication.
2. Section 1.4. Cautions / need for further advice / circumstances when further advice should be sought from a prescriber : addition of the statement “However, the manufacturer advises that it should be used during pregnancy only if the potential benefits to be derived outweigh the possible risks involved, as it is not known whether nystatin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.”

PGD for Nystatin oral suspension(Review date March 2028)

Oral thrush patient assessment form

Updated JN 27/04/26